Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 6/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | PDE8B | O95263 | 1/20 | 0.35 |
| ▸ | MAP3K12 | Q12852 | 5/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15131792 | 0.89 | MTOR (0.41) | MTORPIK3CAMAP4K4 | |
| SCHEMBL807978 | 0.87 | MTOR (0.46) | MTORPIK3CAMAP3K12 | |
| SCHEMBL808272 | 0.87 | MTOR (0.46) | MTORPIK3CATNFMAP3K12 | |
| SCHEMBL807979 | 0.86 | MAP3K12 (0.40) | MTORPIK3CAMAP3K12 | |
| SCHEMBL10070700 | 0.85 | MTOR (0.46) | MTORPIK3CAMAP3K12MAP4K4 | |
| SCHEMBL10070651 | 0.84 | MAP3K12 (0.46) | MTORPIK3CAMAP3K12MAP4K4 | |
| SCHEMBL10070703 | 0.84 | MTOR (0.40) | MTORPIK3CATNFALDH1A1LMNA | |
| SCHEMBL796725 | 0.83 | MAP3K12 (0.40) | MTORPIK3CAMAP3K12MAP4K4 | |
| SCHEMBL15131778 | 0.82 | PIK3CA (0.45) | MTORPIK3CAMAP3K12 | |
| SCHEMBL15133595 | 0.82 | MAP3K12 (0.45) | MTORPIK3CAMAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181264-B2 | Fused heteroaryls and their uses | HUTCHISON MEDIPHARMA LIMITED (CN) | 2015-11-10 | — | — | US | disclosed |
| US-20130190307-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-07-25 | — | — | US | disclosed |
| WO-2012034526-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190307-A1 | FUSED HETEROARYLS AND THEIR USES | FARS2, TIAL1, DHFR | MTOR 4193/4885PIK3CA 1962/4885TNF 3966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.